Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?

Is (IDXX) Outperforming Other Medical Stocks This Year?

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Here's Why You Should Retain IDEXX Laboratories Stock Now

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Idexx Laboratories (IDXX) Q4 Earnings Expected to Decline

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

IDEXX Launches Cytology Service to Upgrade Veterinary Care

IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.

Sanghamitra Saha headshot

S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF

The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.

Sanghamitra Saha headshot

Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks

Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 9.73% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Urmimala Biswas headshot

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?

Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

Investors continue to be optimistic about IDEXX's (IDXX) performance.

IDEXX's Kidney Function Test Included in IRIS Staging Views

IDEXX (IDXX) is upbeat about the inclusion and approval of the SDMA-based renal care staging guidelines.

Idexx (IDXX) Up 8% Since Last Earnings Report: Can It Continue?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now

Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.

3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance

IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.

Idexx Laboratories (IDXX) Q2 Earnings Surpass Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 4.38% and -1.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?